Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023

BUY
$6.56 - $10.95 $450,875 - $752,604
68,731 Added 67.72%
170,230 $1.17 Million
Q2 2023

Aug 14, 2023

SELL
$7.89 - $10.64 $983,906 - $1.33 Million
-124,703 Reduced 55.13%
101,499 $1.05 Million
Q1 2023

May 15, 2023

SELL
$7.07 - $17.95 $2.66 Million - $6.75 Million
-376,317 Reduced 62.46%
226,202 $1.83 Million
Q4 2022

Feb 14, 2023

SELL
$14.33 - $18.37 $1.35 Million - $1.74 Million
-94,488 Reduced 13.56%
602,519 $9.49 Million
Q3 2022

Nov 14, 2022

BUY
$13.07 - $18.22 $986,131 - $1.37 Million
75,450 Added 12.14%
697,007 $11 Million
Q2 2022

Aug 15, 2022

BUY
$10.16 - $17.08 $6.32 Million - $10.6 Million
621,557 New
621,557 $8.68 Million
Q4 2021

Feb 14, 2022

SELL
$12.27 - $18.49 $7.3 Million - $11 Million
-594,768 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$13.38 - $18.8 $7.96 Million - $11.2 Million
594,768 New
594,768 $10.7 Million

Others Institutions Holding ACRS

About Aclaris Therapeutics, Inc.


  • Ticker ACRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 66,671,800
  • Market Cap $253M
  • Description
  • Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...
More about ACRS
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.